The effect of taurolidine on experimental thrombus formationKAPTANOGLU, Levent; KUCUK, Hasan Fehmi; COLAK, Elif et al.European journal of pharmacology. 2008, Vol 578, Num 2-3, pp 238-241, issn 0014-2999, 4 p.Article

Extending the role of antithrombotic agents: An example based on the low-molecular-weight heparin, tinzaparinHAINER, James W; SPROGEL, Per; LINDENSTROEM, Ewa et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 3-9, issn 0094-6176, 7 p., SUP1Conference Paper

Heparin and low-molecular-weight heparin : Current use of biologicals in thrombosis and haemostasisGRAY, Elaine; MULLOY, Barbara; BARROWCLIFFE, Trevor W et al.Thrombosis and haemostasis. 2008, Vol 99, Num 5, pp 807-818, issn 0340-6245, 12 p.Article

Structural features of low-molecular-weight heparins affecting their affinity to antithrombinBISIO, Antonella; VECCHIETTI, Davide; CITTERIO, Laura et al.Thrombosis and haemostasis. 2009, Vol 102, Num 5, pp 865-873, issn 0340-6245, 9 p.Conference Paper

Long-Term Use of Low-Molecular-Weight Heparin in Hemodialysis Patients : A 7-Year ExperienceBERNIEH, B; BOOBES, Y; AL HAKIM, M. R et al.Blood purification. 2009, Vol 27, Num 3, pp 242-245, issn 0253-5068, 4 p.Article

Development of generic low molecular weight heparins: A perspectiveFAREED, Jawed; LEONG, Wendy; HOPPENSTEADT, Debra A et al.Hematology/oncology clinics of North America. 2005, Vol 19, Num 1, pp v-vi, issn 0889-8588, 18 p.Article

Differentiating Low-Molecular-Weight Heparins Based on Chemical, Biological, and Pharmacologic Properties : Implications for the Development of Generic Versions of Low-Molecular-Weight HeparinsJESKE, Walter P; WALENGA, Jeanine M; HOPPENSTEADT, Debra A et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, Num 1, pp 74-85, issn 0094-6176, 12 p.Article

Low-molecular-weight heparin in pediatric patientsSUTOR, Anton Heinz; CHAN, Anthony K. C; MASSICOTTE, Patricia et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, pp 31-39, issn 0094-6176, 9 p., SUP1Conference Paper

Hospital guidelines for use of low-molecular-weight heparinsNUTESCU, Edith A; LEWIS, Richard K; FINLEY, Jamie M et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 7-8, pp 1072-1081, issn 1060-0280, 10 p.Article

Clinical Differentiation of Low Molecular Weight HeparinsMAMMEN, Eberhard F; ARCELUS, Juan; MESSMORE, Harry et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, Num 8, issn 0094-6176, A45-A55Article

Low molecular weight heparin in childrenALBISETTI, Manuela; ANDREW, Maureen.European journal of pediatrics. 2002, Vol 161, Num 2, pp 71-77, issn 0340-6199Article

Attention à l'administration itérative d'HBPM au voyageurLECOMPTE, Thomas.Archives des maladies du coeur et des vaisseaux. Pratique. 2005, Num 136, issn 1261-694X, p. 10Article

Timing of postpartum enoxaparin administration and severe postpartum hemorrhageFREEDMAN, Rachel A; BAUER, Kenneth A; NEUBERG, Donna S et al.Blood coagulation & fibrinolysis. 2008, Vol 19, Num 1, pp 55-59, issn 0957-5235, 5 p.Article

Differential effects of heparin and low molecular weight heparin on osteoblastogenesis and adipogenesis in vitroOSIP, Stephanie L; BUTCHER, Martin; YOUNG, Edward et al.Thrombosis and haemostasis. 2004, Vol 92, Num 4, pp 803-810, issn 0340-6245, 8 p.Article

Low molecular weight heparin in pregnancy: current issuesGREER, Ian; HUNT, Beverley J.British journal of haematology. 2005, Vol 128, Num 5, pp 593-601, issn 0007-1048, 9 p.Article

The potential for circular dichroism as an additional facile and sensitive method of monitoring low-molecular-weight heparins and heparinoidsRUDD, Timothy R; SKIDMORE, Mark A; GUIMOND, Scott E et al.Thrombosis and haemostasis. 2009, Vol 102, Num 5, pp 874-878, issn 0340-6245, 5 p.Conference Paper

Guidelines on the use and monitoring of heparinBAGLIN, T; BARROWCLIFFE, T. W; COHEN, A et al.British journal of haematology. 2006, Vol 133, Num 1, pp 19-34, issn 0007-1048, 16 p.Article

A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparinJESKE, Walter P; HOPPENSTEADT, Debra; GRAY, Angel et al.Thrombosis research. 2011, Vol 128, Num 4, pp 361-367, issn 0049-3848, 7 p.Article

A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulationBARBOUR, Linda A; OJA, Janet L; SCHULTZ, Lisa K et al.American journal of obstetrics and gynecology. 2004, Vol 191, Num 3, pp 1024-1029, issn 0002-9378, 6 p.Article

Etude rétrospective de l'écho-Doppler veineux dans 111 cas de prothèse totale de hanche opérés en 2001 au CHBAH = Echo Doppler post total hip arthroplasty: Retrospective study of 111 patients at CHBAHDI PANFILO, A; CORNETTE, M.RMLG. Revue médicale de Liège. 2004, Vol 59, Num 9, pp 497-503, issn 0370-629X, 7 p.Article

Effect of 3.2 vs. 3.8% sodium citrate concentration on anti-Xa levels for patients on therapeutic low molecular weight heparinPAYNE, S; MACKINNON, K; KEENEY, M et al.Clinical and laboratory haematology. 2003, Vol 25, Num 5, pp 317-319, issn 0141-9854, 3 p.Article

An evaluation of low molecular weight heparin and hyperbaric oxygen treatment in the prevention of intra-abdominal adhesions and wound healingARIKAN, Soykan; ADAS, Gokhan; BARUT, Gul et al.The American journal of surgery. 2005, Vol 189, Num 2, pp 155-160, issn 0002-9610, 6 p.Article

Counteracting the effects of anticoagulants and antiplatelet agents during neurosurgical emergencies. CommentaryPOWNER, David J; HARTWELL, Elizabeth A; HOOTS, W. Keith et al.Neurosurgery. 2005, Vol 57, Num 5, pp 823-831, issn 0148-396X, 9 p.Article

Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitorMOUSA, Shaker A; MOHAMED, S.Thrombosis and haemostasis. 2004, Vol 92, Num 3, pp 627-633, issn 0340-6245, 7 p.Article

Localization of heparin and low-molecular-weight heparin in the rat kidneyYOUNG, Edward; DOUROS, Vivian; PODOR, Thomas J et al.Thrombosis and haemostasis. 2004, Vol 91, Num 5, pp 927-934, issn 0340-6245, 8 p.Article